Home › Medical › Puberty blockers
Puberty blockers
Puberty blockers are medications (GnRH analogues such as triptorelin or leuprorelin) that suppress the hormonal drivers of puberty. In gender care they are given to children who meet the diagnostic criteria for gender dysphoria, at the moment puberty starts. The picture used for years — a harmless 'pause button' — has been overtaken by recent international evaluations.
Not a 'reversible pause'
The claim that puberty blockers are 'fully reversible' and simply 'buy time' is no longer supported by the available evidence. Three observations are crucial:
- ~98% progression to sex hormones: in both the original Dutch cohort and the British Tavistock data, virtually everyone who started on blockers went on to irreversible hormones. In practice it functions not as an open delay but as a step into lifelong medicalisation.
- Effect on puberty itself: puberty is not just a hormonal switch but a developmental period during which body, brain and sexual identity crystallise. That development is suppressed — not 'paused'.
- No comparison with natural development: pre-protocol research showed that the majority of children with dysphoria grow out of it during puberty without medication (desistance). By suppressing puberty, precisely this natural pathway is blocked.
Known physical effects
- Bone: significant loss of bone density during treatment, at the very moment when bone mass peaks. Whether this recovers fully is unknown.
- Brain: adolescent brain development — including executive function, emotion regulation, and social cognition — runs in parallel and in interaction with sex hormones. Research (among others in sheep by Hough, and cognitive studies by Baxendale) points to lasting effects. There are no long-term human studies that can dispel this uncertainty.
- Fertility: when blockers are immediately followed by sex hormones, the gonads have never developed. Gamete cryopreservation is then practically impossible. Permanent infertility is a likely consequence of the full Dutch Protocol pathway.
- Sexual function: in boys, the penis grows during puberty. Suppression means that any later vaginoplasty has less tissue available. In both sexes, anorgasmia/reduced sexual function after a full pathway is documented.
- Height and build: growth and closure of growth plates proceed atypically under blockers.
Scientific debate
The NICE evaluation (2020) rated the available evidence as 'very low quality'. The Cass Review (2024) came to the same conclusion and recommended that puberty blockers in gender dysphoria be used only in a research setting. Michael Biggs (Oxford) analysed the British and Dutch data and concluded that the original claim of psychological well-being does not replicate.
International policy changes
- UK: permanent ban outside research (2024).
- Sweden: use of the Dutch Protocol formally ended for minors (2022).
- Finland: only in strictly indicated exceptional cases (COHERE, 2020).
- Denmark: sharply restricted (Sundhedsstyrelsen, 2023).
- Norway: treatment classified as experimental (Helsedirektoratet, 2023).
In the Netherlands — the country of origin — puberty blockers are still available through specialised gender clinics, without a comparable formal reorientation.
Alternatives
Sweden, Finland and the UK now opt for an approach with psychotherapeutic support as the first step, with attention to underlying problems (autism, trauma, internalising disorders), and with patience for the natural development of the child. Social transition is also viewed with more restraint in those countries, because research suggests that early social transition itself may increase the chance of persistent dysphoria.